SYK STRYKER CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 310764 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.9%
TTM net income YoY23.1%
TTM EPS YoY23.4%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR11.9%
Margins
Gross margin65.3%
Operating margin20.7%
Net margin13.8%
FCF margin17.4%
EBITDA margin26.8%
Returns
ROE16.0%
ROA7.7%
ROIC (approx.)11.0%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets50.4%
Debt / equity0.64x
Current ratio2.18x
Interest coverage9.27x
Cash quality & payout
Operating cash flow / net income1.50x
Accruals ratio-3.9%
Payout ratio36.8%
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.52B | $6.59B | $6.02B | $7.17B | $6.06B | $6.02B | $5.87B | $6.44B |
| Cost of revenue | $2.27B | $2.09B | $2.21B | $2.54B | $2.21B | $2.18B | $2.12B | $2.26B |
| Gross profit | $4.25B | $4.50B | $3.81B | $4.63B | $3.85B | $3.84B | $3.74B | $4.17B |
| R&D expense | $433.00M | $434.00M | $413.00M | $401.00M | $410.00M | $407.00M | $405.00M | $358.00M |
| SG&A expense | $2.31B | $2.23B | $2.28B | $2.23B | $2.04B | $2.08B | $2.30B | $2.10B |
| Operating income | $1.03B | $1.66B | $936.00M | $1.80B | $1.14B | $1.11B | $837.00M | $581.00M |
| Interest expense | $143.00M | $141.00M | $148.00M | $154.00M | $157.00M | $159.00M | $137.00M | $104.00M |
| Pretax income | $997.00M | $1.56B | $850.00M | $1.71B | $1.03B | $1.02B | $764.00M | $528.00M |
| Income tax | $244.00M | $288.00M | $105.00M | $856.00M | $170.00M | $132.00M | $110.00M | -$18.00M |
| Net income | $753.00M | $1.28B | $745.00M | $849.00M | $859.00M | $884.00M | $654.00M | $546.00M |
| EBITDA | $1.43B | $2.06B | $1.33B | $2.22B | $1.54B | $1.50B | $1.20B | $927.00M |
| EPS (basic) | 1.97 | 3.32 | 1.95 | 2.21 | 2.25 | 2.32 | 1.71 | 1.43 |
| EPS (diluted) | 1.96 | 3.30 | 1.93 | 2.20 | 2.22 | 2.29 | 1.69 | 1.41 |
| Dividends declared per share | 0.88 | 0.88 | 0.88 | 0.88 | 0.84 | 0.84 | 0.84 | 0.84 |
| Weighted avg. shares (diluted) | 384.70M | 386.00M | 386.50M | — | 386.70M | 386.40M | 386.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.27B | $3.39B | $2.88B | $4.01B | $3.26B | $2.38B | $2.32B | $3.65B |
| Short-term investments | $0 | $85.00M | $87.00M | $89.00M | $87.00M | $89.00M | $89.00M | $91.00M |
| Receivables | $3.69B | $3.74B | $3.57B | $4.04B | $3.64B | $3.92B | $3.96B | $3.99B |
| Inventory | $5.75B | $5.52B | $5.42B | $5.31B | $5.37B | $5.29B | $5.11B | $4.77B |
| Current assets | $14.18B | $14.42B | $13.34B | $14.76B | $13.71B | $13.00B | $13.02B | $14.85B |
| PP&E, net | $4.05B | $3.96B | $3.89B | $3.88B | $3.73B | $3.70B | $3.54B | $3.45B |
| Goodwill | $19.33B | $19.58B | $19.19B | $19.29B | $19.26B | $19.18B | $19.09B | $15.86B |
| Intangibles | $5.54B | $5.74B | $5.52B | $5.68B | $5.84B | $5.96B | $6.13B | $4.39B |
| Total assets | $47.25B | $47.93B | $46.29B | $47.84B | $47.06B | $46.33B | $46.01B | $42.97B |
| Current liabilities | $6.50B | $6.68B | $6.32B | $7.79B | $7.41B | $7.29B | $7.93B | $7.62B |
| Short-term debt | $754.00M | $750.00M | $499.00M | $1.00B | $1.75B | $1.75B | $2.40B | $1.41B |
| Long-term debt | $14.18B | $14.19B | $14.22B | $14.86B | $14.85B | $14.83B | $14.38B | $12.19B |
| Total debt | $14.93B | $14.94B | $14.72B | $15.86B | $16.59B | $16.58B | $16.78B | $13.60B |
| Total liabilities | $23.79B | $23.94B | $23.31B | $25.42B | $25.27B | $25.14B | $25.08B | $22.34B |
| Shareholders' equity | $23.46B | $23.99B | $22.98B | $22.42B | $21.79B | $21.19B | $20.93B | $20.63B |
| Net debt | $11.66B | $11.55B | $11.85B | $11.85B | $13.34B | $14.21B | $14.46B | $9.95B |
| Cash flow statement | ||||||||
| Operating cash flow | $1.46B | $1.26B | $581.00M | $2.14B | $1.54B | $1.11B | $250.00M | $1.93B |
| Capital expenditure | $237.00M | $202.00M | $166.00M | $268.00M | $187.00M | $183.00M | $123.00M | $266.00M |
| Free cash flow | $1.22B | $1.06B | $415.00M | $1.88B | $1.35B | $928.00M | $127.00M | $1.67B |
| Investing cash flow | -$187.00M | -$639.00M | -$185.00M | -$305.00M | -$321.00M | -$104.00M | -$4.14B | -$303.00M |
| Financing cash flow | -$1.39B | -$95.00M | -$1.51B | -$1.09B | -$339.00M | -$989.00M | $2.53B | -$1.79B |
| Depreciation & amortization | $397.00M | $404.00M | $397.00M | $417.00M | $402.00M | $387.00M | $361.00M | $346.00M |
| Stock-based compensation | $67.00M | $54.00M | $87.00M | $48.00M | $62.00M | $49.00M | $84.00M | $45.00M |
| Dividends paid | $338.00M | $337.00M | $337.00M | $321.00M | $322.00M | $321.00M | $320.00M | $305.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.